Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$62.00 USD
-1.31 (-2.07%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $61.80 -0.20 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.00 USD
-1.31 (-2.07%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $61.80 -0.20 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
by Zacks Equity Research
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
by Zacks Equity Research
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
by Zacks Equity Research
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Brian Big Idea On Technical Analysis
by Brian Bolan
A look at three stocks where technical analysis can help and the TAZR service.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.